Earnings summaries and quarterly performance for IRONWOOD PHARMACEUTICALS.
Executive leadership at IRONWOOD PHARMACEUTICALS.
Board of directors at IRONWOOD PHARMACEUTICALS.
Research analysts who have asked questions during IRONWOOD PHARMACEUTICALS earnings calls.
David Amsellem
Piper Sandler Companies
4 questions for IRWD
Also covers: ABBV, ALKS, AMGN +27 more
JB
Jason Butler
JMP Citizens
4 questions for IRWD
Also covers: ACAD, AQST, ATHA +9 more
AL
Amy Li
Jefferies Financial Group Inc.
3 questions for IRWD
Also covers: ARGX, JAZZ, MDGL
Mohit Bansal
Wells Fargo & Company
3 questions for IRWD
Also covers: ABBV, AMGN, BMRN +16 more
Chase Knickerbocker
Craig-Hallum Capital Group
2 questions for IRWD
Also covers: AVDL, BFLY, BVS +17 more
Matthew Cowper
Leerink Partners
2 questions for IRWD
Also covers: ADAP, IMUX
TC
Timothy Chiang
Capital One
2 questions for IRWD
Also covers: AKYA, ISR, OTLK
Katherine Wang
Jefferies
1 question for IRWD
Also covers: ALKS, APLS
ND
Natalya Davies
Intron Health Research
1 question for IRWD
Recent press releases and 8-K filings for IRWD.
Ironwood Pharmaceuticals Issues Strong 2026 Guidance and Reaffirms 2025 Outlook
IRWD
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Ironwood Pharmaceuticals provided 2026 guidance projecting LINZESS U.S. net sales of $1.125\u2013$1.175 billion, total revenue of $450\u2013$475 million, and adjusted EBITDA above $300 million, while reaffirming its 2025 guidance.
- The company plans to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026 and noted that an effective January 1, 2026, reduction in the LINZESS list price is expected to increase net sales.
- Following the guidance release, IRWD shares rose approximately 28.78% in premarket trading on unusually high trading volume.
- Third-party financial metrics, however, flagged potential balance-sheet risk, including an Altman Z-Score of \u22123.4, a market cap of around $548.2 million, and trailing-12-month revenue of about $338.99 million.
9 hours ago
Ironwood Pharmaceuticals Announces FY 2026 Financial Guidance and Maintains FY 2025 Guidance
IRWD
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Ironwood Pharmaceuticals announced full-year 2026 financial guidance, projecting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA of greater than $300 million.
- The company is maintaining its full-year 2025 financial guidance, with expected LINZESS U.S. net sales of $860 - $890 million, total revenue of $290 - $310 million, and adjusted EBITDA of greater than $135 million.
- Ironwood ended Q4 2025 with greater than $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026.
- Effective January 1, 2026, the LINZESS list price was lowered, which is expected to drive higher net sales in 2026 due to the elimination of the inflationary component of statutory required rebates.
12 hours ago
Ironwood Pharmaceuticals Maintains FY 2025 Guidance and Announces FY 2026 Guidance
IRWD
Guidance Update
Earnings
- Ironwood Pharmaceuticals maintained its full-year 2025 financial guidance and announced full-year 2026 financial guidance.
- For FY 2026, the company anticipates LINZESS® U.S. net sales between $1.125 and $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA greater than $300 million.
- The company ended Q4 2025 with over $200 million in cash and cash equivalents.
- Effective January 1, 2026, the LINZESS list price was lowered, which is projected to result in higher net sales in 2026 due to the elimination of the inflationary component of statutory required rebates.
12 hours ago
Ironwood Pharmaceuticals Reports Strong Q3 2025 Results and Raises Guidance
IRWD
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Ironwood Pharmaceuticals reported strong financial results for Q3 2025, with revenue reaching $122.06 million, a 33.3% year-over-year increase, and a Non-GAAP EPS of $0.24, exceeding expectations.
- LINZESS U.S. net sales were $315 million in Q3 2025, representing a 40% year-over-year increase, and the FDA approved LINZESS for pediatric IBS-C.
- The company raised its full-year 2025 financial guidance, projecting U.S. LINZESS net sales between $860 million and $890 million and total revenue between $290 million and $310 million.
- Ironwood is advancing its apraglutide program for short bowel syndrome, with a Phase 3 trial planned for 2026, and is exploring strategic alternatives to maximize shareholder value.
- Despite these positive results, Wall Street analysts remain cautious, rating the stock as a 'hold' due to concerns about growth sustainability and heavy reliance on a single product.
Nov 10, 2025, 12:44 PM
Ironwood Pharmaceuticals Reports Q4 and Full Year 2024 Results and Provides 2025 Guidance
IRWD
Earnings
Guidance Update
Product Launch
- Ironwood Pharmaceuticals reported full-year 2024 LINZESS U.S. net sales of $916 million and total revenue of $351.4 million, with GAAP net income of $1.8 million and adjusted EBITDA of $100.6 million.
- The company provided 2025 guidance, expecting U.S. LINZESS net sales between $800 million and $850 million, Ironwood revenue between $260 million and $290 million, and adjusted EBITDA (excluding stock-based compensation) of greater than $85 million.
- Ironwood initiated the rolling NDA submission for apraglutide, with a complete submission expected in the third quarter of 2025, aiming for it to be the first long-acting GLP-2 for short bowel syndrome.
- LINZESS prescription demand grew 11% for the full year 2024, marking the eighth consecutive quarter of double-digit new-to-brand volume growth.
- The company restructured its business to focus on apraglutide, leading to a roughly $55 million decrease in 2024 operating expenses, primarily in SG&A, with the full impact of cost savings expected by Q2 2025.
Feb 27, 2025, 1:30 PM
Ironwood Pharmaceuticals Reports Q4 and Full Year 2024 Results, Initiates Aperaglutide NDA Submission, and Provides 2025 Guidance
IRWD
Earnings
Guidance Update
Product Launch
- Ironwood Pharmaceuticals reported $916 million in Linzess U.S. net sales and $351.4 million in total revenue for the full year 2024, ending the year with $88.6 million in cash and cash equivalents and $254 million in total liquidity.
- The company initiated a rolling NDA submission for aperaglutide, its potential blockbuster therapy for short bowel syndrome, with a complete submission expected in Q3 2025.
- For 2025, Ironwood projects Linzess U.S. net sales between $800 million and $850 million and total Ironwood revenue between $260 million and $290 million, with adjusted EBITDA (excluding stock-based compensation) greater than $85 million.
- Linzess prescription demand grew 11% year-over-year in 2024, with expectations for continued high single-digit demand growth in 2025, though pricing headwinds from the Medicare Part D redesign are anticipated.
Feb 27, 2025, 1:30 PM
Quarterly earnings call transcripts for IRONWOOD PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more